Rigetti Computing vs. Quantum Computing: Which Quantum Tech Stock Is a Better Buy in 2026?

Rigetti is favored over Quantum Computing despite both companies posting heavy losses and extreme valuations, with Rigetti generating $7.1 million of 2025 revenue versus Quantum Computing’s roughly $682,000. The article highlights improving 2026 momentum for Rigetti, including Q1 revenue of $4.4 million, a U.S. government contract worth up to $100 million, and a more widely adopted superconducting approach. Quantum Computing also grew revenue sharply to $682,000 and Q1 sales to $3.7 million, but still faces manufacturing and supply-chain/geopolitical risks.

Analysis

The market is still pricing these as science projects, but the second-order driver is not technical superiority alone — it’s funding durability. Rigetti’s path is more legible because government-backed demand can function like a quasi-anchor customer, which lowers near-term financing risk and supports better capital access versus a pure commercial story. That said, both names remain highly dilution-sensitive; in this stage, equity value is more about runway and contract cadence than “true” operating leverage.

The interesting competitive dynamic is that superconducting hardware has a more credible ecosystem path because it can piggyback on the broader tooling stack already being built by larger incumbents, while photonics may require more parallel development in packaging, foundry process control, and integration. That makes QUBT’s growth profile potentially more convex if it works, but also more brittle if conversion from prototype to repeatable manufacturing stalls. In practice, the gap between lab success and bankable revenue is likely longer for QUBT, and that lag matters because cash burn is still outrunning commercial traction by a wide margin.

The contrarian take is that the “cheaper” name on P/S is not necessarily the better risk/reward once you adjust for contract quality and funding mix. Rigetti’s valuation still looks extreme, but the market may be underestimating how much a single large public-sector award can re-rate the story by extending runway and validating the platform. For QUBT, the recent revenue acceleration is the kind of base-rate trap that often attracts momentum capital too early; without manufacturing proof points, the next 6-12 months likely produce volatility rather than clean operating leverage.

Key Decisions for Investors

• Prefer a tactical long RGTIW vs. QUBT pair trade over 3-6 months: Rigetti has the better catalyst path from government validation, while QUBT’s upside is more dependent on execution staying perfect. Use a tight stop if QUBT announces a meaningful commercialization or foundry milestone.
• If initiating exposure, scale into RGTIW only on weakness after contract-related selloffs; the risk/reward is better when the market is ignoring the next award pipeline rather than chasing headline momentum.
• Avoid naked long exposure in QUBT for now unless willing to underwrite 12-24 months of execution risk; if used at all, prefer small call spreads to cap dilution and drawdown risk.
• Sell volatility around earnings or contract announcements in both names if implied vol spikes materially above realized trends; these are story stocks where binary headlines often overprice the move.
• Watch for follow-through in cash burn and equity issuance over the next 1-2 quarters; if either company funds operations with aggressive dilution, the stock can de-rate quickly even on improving revenue.